Drugs.com - FDA MedWatch Alerts

Endo Expands Voluntary Recall of Clonazepam Orally Disintegrating Tablets, USP (C-IV) Due to Potential Product Carton Strength Mislabeling

Audience: Healthcare Provider, Pharmacy, Consumer November 19, 2024 -- Endo, Inc. (OTCQX: NDOI) (“Endo”) announced today that one of its operating subsidiaries, Endo USA, Inc., is expanding its previously announced voluntary recall of...

Feb 9, 2025 - 21:44
 0
Endo Expands Voluntary Recall of Clonazepam Orally Disintegrating Tablets, USP (C-IV) Due to Potential Product Carton Strength Mislabeling
Audience: Healthcare Provider, Pharmacy, Consumer November 19, 2024 -- Endo, Inc. (OTCQX: NDOI) (“Endo”) announced today that one of its operating subsidiaries, Endo USA, Inc., is expanding its previously announced voluntary recall of...
Read More

Tags:

Previous Article

Do Not Purchase or Use Skin-Cap Aerosol Spray Products Because They May Be Harmf...

Next Article

Public Safety Notification on Amniotic Fluid Eyedrops

Related Posts

Gilead Issues Voluntary Nationwide Recall of One Lot of Veklury (Remdesivir) for Injection 100 mg/vial Due to the Presence of a Glass Particle

Gilead Issues Voluntary Nationwide Recall of One Lot of...

Feb 9, 2025  0

Mxbbb Issues Voluntary Nationwide Recall of Umary Acid Hyaluronic Due to the Presence of Diclofenac and Omeprazole

Mxbbb Issues Voluntary Nationwide Recall of Umary Acid ...

Feb 9, 2025  0

Endo USA, Inc. Issues Voluntary, Nationwide Recall of Adrenalin® Chloride Solution (EPINEPHrine Nasal Solution, USP) Due to the Potential for Administration Errors

Endo USA, Inc. Issues Voluntary, Nationwide Recall of A...

Feb 9, 2025  0